Revvity stock rises 5% on strong earnings beat and raised guidance

Revvity reported Q3 adjusted EPS of $1.37 versus $1.30 consensus and revenue of $729 million versus $694.72 million consensus, up 4% year over year; pro forma revenue excluding the pending China Immunodiagnostics divestiture rose 7% to $710 million. The company raised 2026 pro forma adjusted EPS guidance to $5.40-$5.45 and expects approximately $2.86 billion in pro forma revenue, both slightly above consensus. Life Sciences pro forma revenue grew 11%, while Diagnostics pro forma revenue grew 4%; shares rose 5.55% pre-market.

Analysis

The key read-through is the divergence between Life Sciences strength and softer Diagnostics reported revenue: if sustained, it suggests improving research-tool demand rather than a uniform recovery across healthcare spending. That could support a better mix and operating leverage, but the company’s “broad-based” characterization needs confirmation in orders, instrument utilization, and consumables demand; one strong quarter does not establish a durable cycle. Thermo Fisher Scientific and other research-tools providers may benefit from the read-through, while diagnostics-focused peers do not receive the same demand signal.

Near term, the premarket jump raises the bar for follow-through: the guidance increase is modest relative to the reported surprise, so a portion of the good news may already be reflected in the opening price. Over 1–3 months, watch whether organic growth persists and whether the next guidance update is supported by cash conversion and customer demand rather than timing or mix. Over 6–18 months, completion and financial treatment of the China Immunodiagnostics divestiture could complicate reported growth comparisons; verify the transaction timeline and proceeds rather than treating pro forma growth as consolidated growth.

The contrarian risk is that the market extrapolates a single quarter of stronger Life Sciences demand into a broad, durable recovery while Diagnostics remains weaker. No valuation or cash-flow data are supplied, so conviction should depend on post-gap pricing and operating evidence, not an assumed cheap multiple.

Key Decisions for Investors

• Avoid chasing the premarket gap; consider a measured long in RVTY only if the post-open move stabilizes and subsequent commentary confirms sustained organic demand. The thesis weakens if organic growth slows materially or management cuts its outlook.
• For the next 1–3 months, track segment-level organic growth, order trends, and cash conversion. Treat a repeat of Life Sciences strength alongside continued Diagnostics weakness as a narrower thesis, not proof of a company-wide acceleration.
• Use Thermo Fisher Scientific and research-tools peers as read-throughs, not automatic pair-trade shorts: the article supplies no relative valuation, estimate revisions, or comparable demand data to support a relative-value position.
• Verify the China Immunodiagnostics divestiture timing and the reconciliation between pro forma and reported results before underwriting longer-term growth. A delay or materially different financial treatment could muddy comparisons and weaken the catalyst.